Pfizer seeks to prevent HIV
Wall Street Journal (subscription required), January 30, 2008
A new Pfizer Inc. HIV drug will soon be reformulated in an effort to prevent the transmission of the virus. The New York drug maker is expected to announce that it will license its new medicine, Selzentry, to a nonprofit that investigates ways to turn HIV medicines for infected patients into vaginal substances to prevent transmission to women during sex. The partnership offers a low-risk way for Pfizer to find out if the medicine could become a frequently taken drug, while potentially offering an empowering concept to women in the developing world.
- Governors Push to Expand Role of PAs, Telemedicine
- 3 More Pioneer ACOs Say They Will Quit
- Ebola in the U.S.: Reason to Fear, to Hope, to Prepare
- Why Open Payments Irks Physicians
- Top Provider Billing Mistakes Are Changing
- Difficult Patients: It's Not Them, It's You, Doctor
- Overcoming a Payer Mix 'Nightmare'
- Employee Engagement: Make It Meaningful
- These Algorithms Reduce Readmissions
- Payer Calls for More Primary Care Docs, Team Care